

John H Griffin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4455597/john-h-griffin-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

379
papers

17,308
citations

69
h-index

117
g-index

388
ext. papers

18,473
ext. citations

7
avg, IF

6.42
L-index

#	Paper	IF	Citations
379	Skeletal muscle myosin promotes coagulation by binding factor XI via its A3 domain and enhancing thrombin-induced factor XI activation.. <i>Journal of Biological Chemistry</i> , 2022 , 101567	5.4	1
378	Protection of ischemic white matter and oligodendrocytes in mice by 3K3A-activated protein C. <i>Journal of Experimental Medicine</i> , 2022 , 219,	16.6	2
377	3K3A-Activated Protein C Protects the Blood-Brain Barrier and Neurons From Accelerated Ischemic Injury Caused by Pericyte Deficiency in Mice.. <i>Frontiers in Neuroscience</i> , 2022 , 16, 841916	5.1	1
376	Full-length plasma skeletal muscle myosin isoform deficiency is associated with coagulopathy in acutely injured patients.. <i>Journal of Thrombosis and Haemostasis</i> , 2022 ,	15.4	1
375	An optimized method for the isolation of urinary extracellular vesicles for molecular phenotyping: detection of biomarkers for radiation exposure.. <i>Journal of Translational Medicine</i> , 2022 , 20, 199	8.5	0
374	Skeletal Muscle Myosin Is Procoagulant By Binding Factor XI Via Its A3 Domain and Enhancing Factor XI Activation By Thrombin. <i>Blood</i> , 2021 , 138, 441-441	2.2	
373	Sars-Cov-2 Infection Promotes Endothelial Dysfunction and Thrombosis in a Mouse Model of COVID-19. <i>Blood</i> , 2021 , 138, 999-999	2.2	
372	Addendum: American College of Medical Genetics consensus statement on factor V Leiden mutation testing. <i>Genetics in Medicine</i> , 2021 , 23, 2463	8.1	0
371	Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation. <i>Frontiers in Neurology</i> , 2021 , 12, 593582	4.1	2
370	Procoagulant activities of skeletal muscle and cardiac myosins require both myosin protein and myosin-associated anionic phospholipids. <i>Blood</i> , 2021 , 137, 1839-1842	2.2	2
369	Sex-dependent effects of genetic upregulation of activated protein C on delayed effects of acute radiation exposure in the mouse heart, small intestine, and skin. <i>PLoS ONE</i> , 2021 , 16, e0252142	3.7	2
368	Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect. <i>Blood</i> , 2021 , 137, 3428-3442	2.2	4
367	Novel blood coagulation molecules: Skeletal muscle myosin and cardiac myosin. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 7-19	15.4	6
366	Activated protein C and PAR1-derived and PAR3-derived peptides are anti-inflammatory by suppressing macrophage NLRP3 inflammasomes. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 269-280	15.4	3
365	Skeletal muscle myosin and cardiac myosin attenuate heparin@ antithrombin-dependent anticoagulant activity. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 470-477	15.4	1
364	Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently. <i>Circulation Research</i> , 2021 , 128, 513-529	15.7	8
363	PAR1 regulation of CXCL1 expression and neutrophil recruitment to the lung in mice infected with influenza A virus. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 1103-1111	15.4	5

362	COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 506-509	5.1	14
361	FVIIa (Factor VIIa) Induces Biased Cytoprotective Signaling in Mice Through the Cleavage of PAR (Protease-Activated Receptor)-1 at Canonical Arg41 (Arginine41) Site. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 1275-1288	9.4	11
360	3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase. <i>Stroke</i> , 2020 , 51, 2236-2239	6.7	
359	C-terminal residues of activated protein C light chain contribute to its anticoagulant and cytoprotective activities. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1027-1038	15.4	1
358	Cardiac Myosin Promotes Thrombin Generation and Coagulation In Vitro and In Vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 901-913	9.4	7
357	Serum amyloid A4 is a procoagulant apolipoprotein that it is elevated in venous thrombosis patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 217-223	5.1	0
356	Activated Protein C Attenuates Experimental Autoimmune Encephalomyelitis Progression by Enhancing Vascular Integrity and Suppressing Microglial Activation. <i>Frontiers in Neuroscience</i> , 2020 , 14, 333	5.1	11
355	Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus. <i>Blood</i> , 2020 , 135, 1969-1982	2.2	9
354	Activated protein C anticoagulant activity is enhanced by skeletal muscle myosin. <i>Haematologica</i> , 2020 , 105, e424-e427	6.6	5
353	An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms. <i>Blood Advances</i> , 2020 , 4, 3716-3727	7.8	2
352	Plasma skeletal muscle myosin phenotypes identified by immunoblotting are associated with pulmonary embolism occurrence in young adults. <i>Thrombosis Research</i> , 2020 , 189, 88-92	8.2	4
351	Novel exomic rare variants associated with venous thrombosis. <i>British Journal of Haematology</i> , 2020 , 190, 783-786	4.5	10
350	Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis. <i>Blood</i> , 2019 , 134, 1119-1131	2.2	24
349	Neuroprotection and vasculoprotection using genetically targeted protease-ligands. <i>Brain Research</i> , 2019 , 1715, 13-20	3.7	4
348	Activated protein C ameliorates chronic graft-versus-host disease by PAR1-dependent biased cell signaling on T cells. <i>Blood</i> , 2019 , 134, 776-781	2.2	6
347	Molecular Interaction Site on Procoagulant Skeletal Muscle Myosin for Factor Xa-Dependent Prothrombin Activation. <i>Blood</i> , 2019 , 134, 3622-3622	2.2	1
346	Factor VIIa Induces Biased Cytoprotective Signaling through the Cleavage of Protease Activated Receptor 1 at Canonical Arg41 Site. <i>Blood</i> , 2019 , 134, 481-481	2.2	
345	Cardiac Myosin Acts Is a Potent Procoagulant in Vitro and In Vivo. <i>Blood</i> , 2019 , 134, 3632-3632	2.2	

344	Molecular interaction site on procoagulant myosin for factor Xa-dependent prothrombin activation. <i>Journal of Biological Chemistry</i> , 2019 , 294, 15176-15181	5.4	10
343	Cardiac and Skeletal Muscle Myosin Exert Procoagulant Effects. <i>Shock</i> , 2019 , 52, 554-555	3.4	10
342	Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. <i>Annals of Neurology</i> , 2019 , 85, 125-136	9.4	63
341	3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice. <i>Journal of Experimental Medicine</i> , 2019 , 216, 279-293	16.6	35
340	α -Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC: α M Levels Are Associated with Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 630-638	7	8
339	SCH79797 improves outcomes in experimental bacterial pneumonia by boosting neutrophil killing and direct antibiotic activity. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1586-1594	5.1	11
338	Regulation of immune cell signaling by activated protein C. <i>Journal of Leukocyte Biology</i> , 2018 , 103, 1197-1205	6.5	8
337	The TLR4-PAR1 Axis Regulates Bone Marrow Mesenchymal Stromal Cell Survival and Therapeutic Capacity in Experimental Bacterial Pneumonia. <i>Stem Cells</i> , 2018 , 36, 796-806	5.8	15
336	PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke. <i>Blood</i> , 2018 , 131, 1163-1171	2.2	54
335	Targeting anticoagulant protein S to improve hemostasis in hemophilia. <i>Blood</i> , 2018 , 131, 1360-1371	2.2	38
334	Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C. <i>Neuropharmacology</i> , 2018 , 134, 293-301	5.5	11
333	Activated protein C, protease activated receptor 1, and neuroprotection. <i>Blood</i> , 2018 , 132, 159-169	2.2	63
332	Design of a DNA-Programmed Plasminogen Activator. <i>Journal of the American Chemical Society</i> , 2018 , 140, 15516-15524	16.4	13
331	Activated protein C inhibits neutrophil extracellular trap formation and activation. <i>Journal of Biological Chemistry</i> , 2017 , 292, 8616-8629	5.4	62
330	Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition. <i>Blood</i> , 2017 , 130, 2664-2677	2.2	79
329	Low level of the plasma sphingolipid, glucosylceramide, is associated with thrombotic diseases. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017 , 1, 33-40	5.1	7
328	Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017 , 1, 93-102	5.1	8
327	Activated protein C light chain provides an extended binding surface for its anticoagulant cofactor, protein S. <i>Blood Advances</i> , 2017 , 1, 1423-1426	7.8	3

326	3K3A-activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice. <i>Nature Medicine</i> , 2016 , 22, 1050-5	50.5	54
325	2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 2143-2151	9.4	26
324	Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding. <i>Pharmaceutical Research</i> , 2016 , 33, 1517-26	4.5	13
323	Apolipoprotein E Receptor 2 Mediates Activated Protein C-Induced Endothelial Akt Activation and Endothelial Barrier Stabilization. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 518-24	9.4	27
322	Activated Protein C (APC) Therapy Ameliorates Chronic Graft Versus Host Disease By Cell Signaling Mechanisms That Require Cleavage at Arg46 in PAR1 on T Cells. <i>Blood</i> , 2016 , 128, 808-808	2.2	
321	Blocking Protein S Improves Hemostasis in Hemophilia a and B. <i>Blood</i> , 2016 , 128, 79-79	2.2	1
320	Novel R41Q- and R46Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for In Vivo Protective Mechanisms of Action for Activated Protein C (APC) in Sepsis and Stroke. <i>Blood</i> , 2016 , 128, 13-13	2.2	
319	Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 551-61	7	17
318	Elevated CETP Lipid Transfer Activity is Associated with the Risk of Venous Thromboembolism. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016 , 23, 1159-1167	4	6
317	Activation-resistant homozygous protein C R229W mutation causing familial perinatal intracranial hemorrhage and delayed onset of thrombosis. <i>Thrombosis Research</i> , 2016 , 143, 17-21	8.2	2
316	Activated protein C promotes neuroprotection: mechanisms and translation to the clinic. <i>Thrombosis Research</i> , 2016 , 141 Suppl 2, S62-4	8.2	21
315	Physiological cerebrovascular remodeling in response to chronic mild hypoxia: A role for activated protein C. <i>Experimental Neurology</i> , 2016 , 283, 396-403	5.7	5
314	Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va. <i>Blood</i> , 2016 , 128, 1870-1878	2.2	30
313	Re-evaluation of the anticoagulant properties of high-density lipoprotein-brief report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 570-2	9.4	11
312	Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data. <i>Blood</i> , 2015 , 126, 1595-600	2.2	30
311	Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice. <i>Blood</i> , 2015 , 126, 2415-23	2.2	27
310	EPCR-dependent PAR2 activation by the blood coagulation initiation complex regulates LPS-triggered interferon responses in mice. <i>Blood</i> , 2015 , 125, 2845-54	2.2	41
309	Activated protein C: biased for translation. <i>Blood</i> , 2015 , 125, 2898-907	2.2	156

308	Exacerbated venous thromboembolism in mice carrying a protein S K196E mutation. <i>Blood</i> , 2015 , 126, 2247-53	2.2	23
307	Arteriovenous Blood Metabolomics: A Readout of Intra-Tissue Metabostasis. <i>Scientific Reports</i> , 2015 , 5, 12757	4.9	47
306	Inhibition of thrombin generation in human plasma by phospholipid transfer protein. <i>Thrombosis Journal</i> , 2015 , 13, 24	5.6	6
305	Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic stroke. <i>Frontiers in Cellular Neuroscience</i> , 2015 , 9, 344	6.1	20
304	Lyso-Sulfatide Binds Factor Xa and Inhibits Thrombin Generation by the Prothrombinase Complex. <i>PLoS ONE</i> , 2015 , 10, e0135025	3.7	2
303	Exome Genotyping Links Venous Thrombosis Risk with the Skeletal Muscle Myosin Gene Cluster and Leads to Discovery of New Family of Procoagulant Factors. <i>Blood</i> , 2015 , 126, 763-763	2.2	2
302	Coagulation Factor V Mediates Inhibition of Tissue Factor Signaling By Activated Protein C. <i>Blood</i> , 2015 , 126, 216-216	2.2	
301	Role of Protein S and Gas6 in the Development of Purpura Fulminans. <i>Blood</i> , 2015 , 126, 1042-1042	2.2	
300	Plasma Constitutive Serum Amyloid A4 Is Procoagulant and Is Elevated in Venous Thrombosis Patients. <i>Blood</i> , 2015 , 126, 3486-3486	2.2	
299	An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C. <i>PLoS ONE</i> , 2014 , 9, e104304	3.7	12
298	Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E1035-42	11.5	150
297	Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant. <i>Journal of Thrombosis and Haemostasis</i> , 2014 , 12, 363-72	15.4	24
296	Gain in translation: heme oxygenase-1 induced by activated protein C promotes thrombus resolution. <i>Journal of Thrombosis and Haemostasis</i> , 2014 , 12, 90-2	15.4	1
295	Warfarin untargeted metabolomics study identifies novel procoagulant ethanolamide plasma lipids. <i>British Journal of Haematology</i> , 2014 , 165, 409-12	4.5	7
294	Cytoprotective-selective activated protein C therapy for ischaemic stroke. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 883-92	7	39
293	Synergistic Effect in Bleed Reduction By superfva and Recombinant Human FVIIa in Vivo Suggests a Novel Bypassing Strategy for Hemophilia Patients with Inhibitors. <i>Blood</i> , 2014 , 124, 692-692	2.2	1
292	Reversal of Novel Oral Anticoagulant (NOAC)-Induced Bleeding in Mice By Engineered superfactor Va. <i>Blood</i> , 2014 , 124, 695-695	2.2	3
291	Novel R41Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for in Vivo Mechanisms of Action for Thrombin (IIa) and Activated Protein C (APC). <i>Blood</i> , 2014 , 124, 99-99	2.2	

290	Acylcarnitines Are Novel Anticoagulant Lipids That Target Factor Xa and That Are Reduced in Plasma of Venous Thrombosis Patients Based on Untargeted and Targeted Metabolomics. <i>Blood</i> , 2014 , 124, 2797-2797	2.2	
289	Antibody SPC-54 provides acute in vivo blockage of the murine protein C system. <i>Blood Cells, Molecules, and Diseases</i> , 2013 , 50, 252-8	2.1	5
288	Removal of Coagulation Factors by the Gamunex \square -C Purification Process. <i>Journal of Allergy and Clinical Immunology</i> , 2013 , 131, AB10	11.5	2
287	Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1. <i>Brain Research</i> , 2013 , 1507, 97-104	3.7	22
286	Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice. <i>Blood Cells, Molecules, and Diseases</i> , 2013 , 51, 104-8	2.1	9
285	An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway. <i>Journal of Neuroscience</i> , 2013 , 33, 6181-90	6.6	44
284	Organ-specific protection against lipopolysaccharide-induced vascular leak is dependent on the endothelial protein C receptor. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013 , 33, 769-76	9.4	31
283	Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats. <i>Stroke</i> , 2013 , 44, 3529-36	6.7	47
282	Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant $\text{\textcircled{Q}}$ anticoagulant activity. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 2059-62	15.4	6
281	Elevated serum amyloid A is associated with venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 358-9	7	11
280	Plasma protein S residues 37-50 mediate its binding to factor Va and inhibition of blood coagulation. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 275-82	7	6
279	Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers. <i>Current Pharmaceutical Design</i> , 2013 , 19, 7479-85	3.3	55
278	An Engineered Factor Fva Prevents Bleeding Induced By Anticoagulant Wild Type Activated Protein C. <i>Blood</i> , 2013 , 122, 203-203	2.2	
277	Reduction Of Histone H1 Cytotoxicity By Activated Protein C and Its Exosite Variants. <i>Blood</i> , 2013 , 122, 2334-2334	2.2	0
276	Activation-Resistant Homozygous Protein C R229W Mutation Causing Familial Perinatal Intracranial Hemorrhage. <i>Blood</i> , 2013 , 122, 3587-3587	2.2	
275	Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. <i>Blood</i> , 2012 , 120, 5237-46	2.2	157
274	Incorporation of disulfide containing protein modules into multivalent antigenic conjugates: generation of antibodies against the thrombin-sensitive region of murine protein S. <i>Journal of the American Chemical Society</i> , 2012 , 134, 19318-21	16.4	9
273	Activated protein C plasma levels in the fasting and postprandial states among patients with previous unprovoked venous thromboembolism. <i>Thrombosis Research</i> , 2012 , 129, 502-7	8.2	2

272	An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. <i>Stroke</i> , 2012 , 43, 2444-9	6.7	59
271	Infrared fluorescence for vascular barrier breach in vivo—a novel method for quantitation of albumin efflux. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 981-91	7	7
270	Protein C anticoagulant and cytoprotective pathways. <i>International Journal of Hematology</i> , 2012 , 95, 333-45	2.3	88
269	Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. <i>Nature Medicine</i> , 2012 , 18, 1123-9	50.5	85
268	Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. <i>Blood</i> , 2012 , 119, 874-83	2.2	85
267	Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. <i>Current Pharmaceutical Design</i> , 2012 , 18, 4215-22	3.3	46
266	Factor V Inhibits PAR2-Mediated Lethal Inflammation. <i>Blood</i> , 2012 , 120, 3360-3360	2.2	1
265	In Vitro and in Vivo Neutralization of Murine Activated Protein C. <i>Blood</i> , 2012 , 120, 3364-3364	2.2	
264	Protection Against Vascular Leakage in Vivo by a Peptide Mimetic of the Novel Tethered Ligand Generated by Non-Canonical Cleavage of Protease Activated Receptor 1 by Activated Protein C. <i>Blood</i> , 2012 , 120, 497-497	2.2	
263	Activated Protein C Cytoprotective Signaling in Endothelial Cells Involves apoER2 and Disabled-1. <i>Blood</i> , 2012 , 120, 1102-1102	2.2	
262	Superior in Vivo Hemostatic Properties of an Engineered Factor Va Variant for Hemophilia Mice. <i>Blood</i> , 2012 , 120, 17-17	2.2	
261	Cytoprotective protein C pathways and implications for stroke and neurological disorders. <i>Trends in Neurosciences</i> , 2011 , 34, 198-209	13.3	107
260	Protein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl D-aspartate-treated neurons via Tyro3-Akt-FKHRL1 signaling pathway. <i>Molecular Neurodegeneration</i> , 2011 , 6, 13	19	24
259	Acylideneoxindoles: a new class of reversible inhibitors of human transglutaminase 2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011 , 21, 2692-6	2.9	52
258	Identification of new inhibitors of protein kinase R guided by statistical modeling. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011 , 21, 4108-14	2.9	17
257	Cytoprotective-selective activated protein C attenuates <i>Pseudomonas aeruginosa</i> -induced lung injury in mice. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011 , 45, 632-41	5.7	33
256	Human thrombomodulin knock-in mice reveal differential effects of human thrombomodulin on thrombosis and atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011 , 31, 2509-17	9.4	7
255	Plasma High Density Lipoprotein and Anticoagulant Response to Activated Protein C (APC) and Protein S. <i>Blood</i> , 2011 , 118, 2249-2249	2.2	1

254	Non-Canonical Cleavage of Protease Activated Receptor 1 (PAR1) by Activated Protein C Provides Novel Insights Into the Repertoire of Cytoprotective and Proinflammatory PAR1 Signaling. <i>Blood</i> , 2011 , 118, 534-534	2.2	1
253	Insight in Protein S Deficiency From Mouse Models. <i>Blood</i> , 2011 , 118, 529-529	2.2	1
252	Warfarin Untargeted Metabolomics Study Identifies Novel Procoagulant Ethanolamide Lipids. <i>Blood</i> , 2011 , 118, 1200-1200	2.2	
251	Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone-binding globulin-like region. <i>Journal of Neuroscience</i> , 2010 , 30, 15521-34	6.6	45
250	Association of Apo(a)isoform size with dyslipoproteinemia in male venous thrombosis patients. <i>Clinica Chimica Acta</i> , 2010 , 411, 1279-83	6.2	4
249	Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2010 , 37, 17-23		16
248	Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. <i>Journal of Clinical Investigation</i> , 2010 , 120, 3167-78	15.9	75
247	Lyso-Sulfatide Binds Factor Xa and Potently Inhibits Thrombin Generation.. <i>Blood</i> , 2010 , 116, 1130-1130	2.2	
246	Plasma Serum Amyloid A Levels Are Increased In Venous Thrombosis Patients and Are Correlated with Blood Coagulability. <i>Blood</i> , 2010 , 116, 155-155	2.2	1
245	Novel Infrared Fluorescence Methodology Defines An Essential Role for Endothelial Protein C Receptor (EPCR) for Protection Against Vascular Leakage In Inflammation. <i>Blood</i> , 2010 , 116, 653-653	2.2	
244	Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 274-9	11.5	115
243	Species-specific anticoagulant and mitogenic activities of murine protein S. <i>Haematologica</i> , 2009 , 94, 1721-31	6.6	18
242	Plasma protein S contains zinc essential for efficient activated protein C-independent anticoagulant activity and binding to factor Xa, but not for efficient binding to tissue factor pathway inhibitor. <i>FASEB Journal</i> , 2009 , 23, 2244-53	0.9	34
241	Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. <i>European Journal of Neuroscience</i> , 2009 , 29, 1119-30	3.5	69
240	Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity. <i>Journal of Neurochemistry</i> , 2009 , 109, 116-24	6	27
239	Human plasma phospholipid transfer protein specific activity is correlated with HDL size: implications for lipoprotein physiology. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2009 , 1791, 206-11	5	20
238	Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. <i>Journal of Clinical Investigation</i> , 2009 , 119, 3437-49	15.9	135
237	Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. <i>Blood</i> , 2009 , 113, 2859-66	2.2	98

236	Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. <i>Blood</i> , 2009 , 113, 5970-8.2		63
235	Generation and phenotypic analysis of protein S-deficient mice. <i>Blood</i> , 2009 , 114, 2307-14	2.2	56
234	Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 724-33	7	65
233	Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 55-61	7	8
232	Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. <i>Journal of Neuroscience</i> , 2008 , 28, 12788-97	6.6	90
231	The thrombin-sensitive region of protein S mediates phospholipid-dependent interaction with factor Xa. <i>Journal of Biological Chemistry</i> , 2008 , 283, 33046-52	5.4	13
230	Failure to validate association of gene polymorphisms in EPCR, PAR-1, FSAP and protein S Tokushima with venous thromboembolism among Californians of European ancestry. <i>Thrombosis and Haemostasis</i> , 2008 , 99, 453-5	7	24
229	Elevated plasma fibronectin levels associated with venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2008 , 100, 224-228	7	8
228	Elevated plasma fibronectin levels associated with venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2008 , 100, 224-8	7	4
227	Activation of the PI3K-Akt Pathway by Activated Protein C Occurs Via a Novel Receptor, Apolipoprotein E Receptor 2 (ApoER2). <i>Blood</i> , 2008 , 112, 695-695	2.2	
226	Factor V as Anticoagulant Cofactor for Activated Protein C in Factor Va Inactivation. <i>Blood</i> , 2008 , 112, 3075-3075	2.2	
225	Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays. <i>Journal of Thrombosis and Haemostasis</i> , 2007 , 5, 102-8	15.4	44
224	Activated protein C. <i>Journal of Thrombosis and Haemostasis</i> , 2007 , 5 Suppl 1, 73-80	15.4	165
223	Activation of protein C and hemodynamic recovery after coronary artery bypass surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007 , 133, 44-51	1.5	14
222	Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. <i>Journal of Biological Chemistry</i> , 2007 , 282, 33022-33	5.4	92
221	Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. <i>Journal of Experimental Medicine</i> , 2007 , 204, 2439-48	16.6	283
220	High-density lipoprotein and the risk of recurrent venous thromboembolism. <i>Circulation</i> , 2007 , 115, 1609-14	6.4	90
219	Characterization of a factor Xa binding site on factor Va near the Arg-506 activated protein C cleavage site. <i>Journal of Biological Chemistry</i> , 2007 , 282, 21848-55	5.4	21

218	Factor Va residues 311-325 represent an activated protein C binding region. <i>Journal of Biological Chemistry</i> , 2007 , 282, 28353-28361	5.4	7
217	Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. <i>Blood</i> , 2007 , 109, 3733-40	2.2	46
216	The cytoprotective protein C pathway. <i>Blood</i> , 2007 , 109, 3161-72	2.2	628
215	Plasma cholesteryl ester transfer protein and blood coagulability. <i>Thrombosis and Haemostasis</i> , 2007 , 98, 1160-1164	7	10
214	In Vivo Anti-Thrombotic Potency of Engineered Activated Protein C Variants.. <i>Blood</i> , 2007 , 110, 2704-2704	2.2	24
213	Preservation of Beneficial TAFI Functions by an Activated Protein C Variant with Normal Cytoprotective Functions but Minimal Anticoagulant Activity.. <i>Blood</i> , 2007 , 110, 268-268	2.2	
212	Plasma cholesteryl ester transfer protein and blood coagulability. <i>Thrombosis and Haemostasis</i> , 2007 , 98, 1160-4	7	5
211	A novel ELISA for mouse activated protein C in plasma. <i>Journal of Immunological Methods</i> , 2006 , 314, 174-81	2.5	16
210	Endothelial and antithrombotic actions of HDL. <i>Circulation Research</i> , 2006 , 98, 1352-64	15.7	475
209	Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. <i>Journal of Biological Chemistry</i> , 2006 , 281, 20077-84	5.4	107
208	Upregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitis. <i>Critical Care</i> , 2006 , 10, R16	10.8	28
207	The promise of protein C. <i>Blood Cells, Molecules, and Diseases</i> , 2006 , 36, 211-6	2.1	39
206	Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities. <i>Frontiers in Bioscience - Landmark</i> , 2006 , 11, 2381-99	2.8	47
205	Graft protein C entrapment is associated with reduced phagocyte activation during reperfusion in human liver transplantation. <i>Critical Care Medicine</i> , 2006 , 34, 426-32	1.4	8
204	Is adiponectin implicated in venous thromboembolism?. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 1151-2	15.4	1
203	Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 1315-22	15.4	38
202	Cholesteryl ester transfer protein genotypes associated with venous thrombosis and dyslipoproteinemia in males. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 2080-2	15.4	7
201	Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates. <i>British Journal of Haematology</i> , 2006 , 132, 197-203	4.5	9

200	Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. <i>Nature Medicine</i> , 2006 , 12, 1278-85	50.5	222
199	Activated protein C in the cardioplegic solution on a porcine model of coronary ischemia-reperfusion has deleterious hemodynamic effects. <i>Cardiovascular Drugs and Therapy</i> , 2006 , 20, 113-21	3.9	5
198	Mechanisms for Mortality Reduction by Activated Protein C in Severe Sepsis.. <i>Blood</i> , 2006 , 108, 1-1	2.2	6
197	Risk of Recurrent Venous Thromboembolism Reduced by High Density Lipoproteins.. <i>Blood</i> , 2006 , 108, 271-271	2.2	1
196	Anti-Inflammatory and Anti-Apoptotic Activities of Activated Protein C Are Independent of Anticoagulant Activity.. <i>Blood</i> , 2006 , 108, 65-65	2.2	3
195	Platelet Factor 4 (PF4) Modulation of Endothelial Protein C Receptor and Thrombomodulin Enhancements of Protein C Activation and TAFI Activation by Thrombin.. <i>Blood</i> , 2006 , 108, 1791-1791	2.2	
194	Cholesterol enhances phospholipid-dependent activated protein C anticoagulant activity. <i>Journal of Thrombosis and Haemostasis</i> , 2005 , 3, 340-5	15.4	2
193	Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide. <i>Journal of Thrombosis and Haemostasis</i> , 2005 , 3, 935-8	15.4	20
192	Activated protein C reduces graft neutrophil activation in clinical renal transplantation. <i>American Journal of Transplantation</i> , 2005 , 5, 2204-12	8.7	16
191	Functional recovery after embolic stroke in rodents by activated protein C. <i>Annals of Neurology</i> , 2005 , 58, 474-7	9.4	63
190	High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. <i>Circulation</i> , 2005 , 112, 893-9	16.7	144
189	Protective Effect of Activated Protein C in Murine Endotoxemia: Mechanism of Action.. <i>Blood</i> , 2005 , 106, 26-26	2.2	6
188	Activated Protein C Light Chain Mutations Distinguish Exosite Residue Requirements for Anticoagulant Versus Cytoprotective Activities.. <i>Blood</i> , 2005 , 106, 29-29	2.2	
187	Efficient Barrier Protective Signaling by Activated Protein C Is Mechanistically Linked to Protein C Activation on Endothelial Cells.. <i>Blood</i> , 2005 , 106, 28-28	2.2	
186	Sphingolipids as bioactive regulators of thrombin generation. <i>Journal of Biological Chemistry</i> , 2004 , 279, 12036-42	5.4	38
185	Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. <i>Diabetes</i> , 2004 , 53, 2804-14	0.9	112
184	Prothrombin residues 473-487 contribute to factor Va binding in the prothrombinase complex. <i>Journal of Biological Chemistry</i> , 2004 , 279, 49019-25	5.4	22
183	Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. <i>Nature Medicine</i> , 2004 , 10, 1379-83	50.5	192

182	Characterization of a thrombomodulin binding site on protein C and its comparison to an activated protein C binding site for factor Va. <i>Proteins: Structure, Function and Bioinformatics</i> , 2004 , 54, 433-41	4.2	16
181	Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. <i>Neuron</i> , 2004 , 41, 563-72	13.9	212
180	Activated protein C and ischemic stroke. <i>Critical Care Medicine</i> , 2004 , 32, S247-53	1.4	33
179	Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. <i>Blood</i> , 2004 , 104, 1740-4	2.2	143
178	Factor Xa Binding Sites on Factor Va in the Prothrombinase Complex.. <i>Blood</i> , 2004 , 104, 1713-1713	2.2	
177	Whole Blood Thromboelastogram Assays Demonstrate Prolonged Factor VIIIa Potency for Recombinant Disulfide Bond-Stabilized Factor VIII Variants.. <i>Blood</i> , 2004 , 104, 2976-2976	2.2	1
176	Targeted Replacement of the Murine Thrombomodulin Gene with Human Thrombomodulin Coding Sequence Results in Decreased Protein C Activation and Enhanced Thrombotic Response to Photochemical Injury.. <i>Blood</i> , 2004 , 104, 2980-2980	2.2	
175	Sustained Pharmacological Activation of Protein C (PC) in Baboons.. <i>Blood</i> , 2004 , 104, 3499-3499	2.2	
174	Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 7830-5	11.5	183
173	Activation of protein C during reperfusion in clinical liver transplantation. <i>Transplantation</i> , 2003 , 75, 467-472	1.2	13
172	Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. <i>Blood</i> , 2003 , 102, 146-51	2.2	61
171	Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. <i>Blood</i> , 2003 , 101, 4797-801	2.2	100
170	Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. <i>Biochemical Journal</i> , 2003 , 373, 65-70	3.8	201
169	Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. <i>Nature Medicine</i> , 2003 , 9, 338-42	50.5	503
168	Enantiotracin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003 , 13, 2239-40	2.9	3
167	Multivalent drug design. Synthesis and in vitro analysis of an array of vancomycin dimers. <i>Journal of the American Chemical Society</i> , 2003 , 125, 6517-31	16.4	60
166	Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. <i>Blood Cells, Molecules, and Diseases</i> , 2003 , 30, 271-6	2.1	59
165	Glucosylceramide, a neutral glycosphingolipid anticoagulant cofactor, enhances the interaction of human- and bovine-activated protein C with negatively charged phospholipid vesicles. <i>Journal of Biological Chemistry</i> , 2003 , 278, 14614-21	5.4	18

164	Protein S confers neuronal protection during ischemic/hypoxic injury in mice. <i>Circulation</i> , 2003 , 107, 1791-6	6.7	68
163	Identification of distinct sequences in human blood coagulation factor Xa and prothrombin essential for substrate and cofactor recognition in the prothrombinase complex. <i>Journal of Biological Chemistry</i> , 2003 , 278, 33312-8	5.4	38
162	Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C. <i>Protein Science</i> , 2002 , 11, 2091-101	6.3	41
161	Coagulation pathways in atherothrombosis. <i>Trends in Cardiovascular Medicine</i> , 2002 , 12, 317-24	6.9	19
160	Factor Va increases the affinity of factor Xa for prothrombin: a binding study using a novel photoactivable thiol-specific fluorescent probe. <i>Chemistry and Biology</i> , 2002 , 9, 485-94		13
159	Low levels of activated protein C in patients with systemic lupus erythematosus do not relate to lupus anticoagulants but to low levels of factor II. <i>British Journal of Haematology</i> , 2002 , 117, 676-84	4.5	7
158	Neutral glycosphingolipid-dependent inactivation of coagulation factor Va by activated protein C and protein S. <i>Journal of Biological Chemistry</i> , 2002 , 277, 8861-5	5.4	13
157	Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys. <i>Circulation</i> , 2002 , 106, 842-6	16.7	17
156	Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C. <i>Journal of Biological Chemistry</i> , 2002 , 277, 28836-40	5.4	60
155	Oral anticoagulation reduces activated protein C less than protein C and other vitamin K-dependent clotting factors. <i>Blood</i> , 2002 , 100, 4232-3	2.2	10
154	Effect of hyperhomocysteinemia on protein C activation and activity. <i>Blood</i> , 2002 , 100, 2108-12	2.2	31
153	Conversion of a plant oxidosqualene-cycloartenol synthase to an oxidosqualene-lanosterol cyclase by random mutagenesis. <i>Biochemistry</i> , 2002 , 41, 8238-44	3.2	36
152	Protein C pathway impairment in nonsymptomatic cigarette smokers. <i>Blood Cells, Molecules, and Diseases</i> , 2002 , 29, 73-82	2.1	14
151	Low protein Z levels and risk of ischemic stroke: differences by diabetic status and gender. <i>Blood Cells, Molecules, and Diseases</i> , 2002 , 29, 139-44	2.1	48
150	Activated protein C-dependent and -independent anticoagulant activities of protein S have different structural requirements. <i>Blood Cells, Molecules, and Diseases</i> , 2002 , 29, 190-9	2.1	15
149	Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. <i>Seminars in Hematology</i> , 2002 , 39, 197-205	4	77
148	Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. <i>Blood</i> , 2001 , 97, 1907-14	2.2	53
147	Activated protein C and inflammation in human myocardium after heart surgery. <i>American Journal of Hematology</i> , 2001 , 67, 210-2	7.1	15

146	Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. <i>Circulation</i> , 2001 , 103, 1799-805	16.7	179
145	Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45, 1210-5	5.9	68
144	American College of Medical Genetics consensus statement on factor V Leiden mutation testing. <i>Genetics in Medicine</i> , 2001 , 3, 139-48	8.1	141
143	Plasma Lipoproteins, Hemostasis and Thrombosis. <i>Thrombosis and Haemostasis</i> , 2001 , 86, 386-394	7	80
142	Anticoagulant Dysfunction of Human Arg352Trp-Activated Protein C Caused by Defective Factor Va Inactivation. <i>Thrombosis and Haemostasis</i> , 2001 , 85, 274-279	7	2
141	Plasma lipoproteins, hemostasis and thrombosis. <i>Thrombosis and Haemostasis</i> , 2001 , 86, 386-94	7	26
140	Conformational changes in activated protein C caused by binding of the first epidermal growth factor-like module of protein S. <i>Biochemical Journal</i> , 2000 , 349 Pt 3, 757-64	3.8	27
139	Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. <i>Critical Care Medicine</i> , 2000 , 28, 2209-16	1.4	226
138	The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. <i>Blood</i> , 2000 , 96, 585-593	2.2	49
137	Causes of thrombophilia yet to be discovered: a personal view. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2000 , 30 Suppl 2, 26-33		
136	Three-dimensional Model of Coagulation Factor Va Bound to Activated Protein C. <i>Thrombosis and Haemostasis</i> , 2000 , 84, 849-857	7	62
135	Chemical synthesis and spontaneous folding of a multidomain protein: anticoagulant microprotein S. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 14074-8	11.5	33
134	Cardiolipin is a normal component of human plasma lipoproteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 1743-8	11.5	86
133	Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. <i>Journal of Biological Chemistry</i> , 2000 , 275, 12410-5	5.4	77
132	Cardiolipin enhances protein C pathway anticoagulant activity. <i>Blood Cells, Molecules, and Diseases</i> , 2000 , 26, 115-23	2.1	19
131	The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. <i>Blood</i> , 2000 , 96, 585-593	2.2	20
130	Extensive Venous and Arterial Thrombosis Associated With an Inhibitor to Activated Protein C. <i>Blood</i> , 1999 , 94, 895-901	2.2	32
129	Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999 , 19, 1744-50	9.4	29

128	C-terminal residues 621-635 of protein S are essential for binding to factor Va. <i>Journal of Biological Chemistry</i> , 1999 , 274, 36187-92	5.4	27
127	Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999 , 19, 2801-6	9.4	116
126	Cardiopulmonary bypass and activation of antithrombotic plasma protein C. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1999 , 118, 422-9; discussion 429-31	1.5	24
125	Protein synthesis by native chemical ligation: expanded scope by using straightforward methodology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 10068-73	11.5	585
124	Two multiplex PCR-based DNA assays for the thrombosis risk factors prothrombin G20210A and coagulation factor V G1691A polymorphisms. <i>Thrombosis Research</i> , 1999 , 93, 265-9	8.2	12
123	Brain-specific protein C activation during carotid artery occlusion in humans. <i>Stroke</i> , 1999 , 30, 542-5	6.7	30
122	High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. <i>Journal of Clinical Investigation</i> , 1999 , 103, 219-27	15.9	166
121	Dermatan Sulfate and LMW Heparin Enhance the Anticoagulant Action of Activated Protein C. <i>Thrombosis and Haemostasis</i> , 1999 , 82, 1462-1468	7	23
120	Chemical synthesis of human protein S thrombin-sensitive module and first epidermal growth factor module. <i>Biopolymers</i> , 1998 , 46, 53-63	2.2	18
119	Synthesis and Properties of Metalloporphyrin Monolayers and Stacked Multilayers Bound to an Electrode via Site Specific Axial Ligation to a Self-Assembled Monolayer. <i>Journal of the American Chemical Society</i> , 1998 , 120, 4478-4487	16.4	144
118	Involvement of amino acid residues 423-429 of human protein S in binding to C4b-binding protein. <i>Blood Cells, Molecules, and Diseases</i> , 1998 , 24, 101-12; discussion 113	2.1	17
117	Homology models of the C domains of blood coagulation factors V and VIII: a proposed membrane binding mode for FV and FVIII C2 domains. <i>Blood Cells, Molecules, and Diseases</i> , 1998 , 24, 448-61	2.1	42
116	Inhibition of prothrombinase by human secretory phospholipase A2 involves binding to factor Xa. <i>Journal of Biological Chemistry</i> , 1998 , 273, 23764-72	5.4	44
115	Binding site for blood coagulation factor Xa involving residues 311-325 in factor Va. <i>Journal of Biological Chemistry</i> , 1998 , 273, 14900-5	5.4	31
114	Upregulation of the antithrombotic protein C pathway at birth. <i>Pediatric Hematology and Oncology</i> , 1998 , 15, 489-99	1.7	9
113	Circulating activated protein C in subjects with heterozygous Gln506-factor V. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1998 , 28, 31-6		2
112	Potent blood coagulant activity of human semen due to prostatesome-bound tissue factor. <i>Biology of Reproduction</i> , 1997 , 56, 757-63	3.9	50
111	Protein S is inducible by interleukin 4 in T cells and inhibits lymphoid cell procoagulant activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 11484-9	11.5	33

110	A Single Genetic Origin for a Common Caucasian Risk Factor for Venous Thrombosis. <i>Blood</i> , 1997 , 89, 397-402	2.2	215
109	Total chemical synthesis of enzymatically active human type II secretory phospholipase A2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 7845-50	11.5	73
108	The Carbohydrate Moiety of Factor V Modulates Inactivation by Activated Protein C. <i>Blood</i> , 1997 , 89, 4348-4354	2.2	20
107	Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va. <i>Protein Science</i> , 1997 , 6, 132-40	6.3	28
106	Activated protein C correlates inversely with thrombin levels in resting healthy individuals. <i>American Journal of Hematology</i> , 1997 , 56, 29-31	7.1	8
105	Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C. <i>Journal of Clinical Investigation</i> , 1997 , 99, 2655-63	15.9	21
104	Novel Vancomycin Dimers with Activity against Vancomycin-Resistant Enterococci. <i>Journal of the American Chemical Society</i> , 1996 , 118, 13107-13108	16.4	122
103	Electrocatalytic Reduction of Dioxygen by Diruthenium Cofacial Diporphyrins Axially-Bound to a Gold-Supported, Self-Assembled Monolayer. <i>Inorganic Chemistry</i> , 1996 , 35, 1751-1752	5.1	35
102	Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va. <i>Protein Science</i> , 1996 , 5, 1883-9	6.3	52
101	Thrombosis in otherwise well children with the factor V Leiden mutation. <i>Journal of Pediatrics</i> , 1996 , 128, 324-8	3.6	53
100	Solid-Phase Total Synthesis of Bacitracin A. <i>Journal of Organic Chemistry</i> , 1996 , 61, 3983-3986	4.2	32
99	Resistance to activated protein C: a common inherited cause of venous thrombosis. <i>Annals of Vascular Surgery</i> , 1996 , 10, 174-7	1.7	13
98	Central venous thrombosis after cardiac operations in children. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1996 , 112, 883-9	1.5	55
97	Design, synthesis and in vitro evaluation of pyridinium ion based cyclase inhibitors and antifungal agents. <i>Bioorganic and Medicinal Chemistry</i> , 1996 , 4, 97-103	3.4	18
96	Steric and Electronic Effects, Enantiospecificity, and Reactive Orientation in DNA Binding/Cleaving by Substituted Derivatives of [SalenMn(III)](+). <i>Inorganic Chemistry</i> , 1996 , 35, 4837-4847	5.1	84
95	Impairments of the protein C system and fibrinolysis in infection-associated stroke. <i>Stroke</i> , 1996 , 27, 2005-11	6.7	94
94	Activated protein C resistance in ischemic stroke not due to factor V arginine506-->glutamine mutation. <i>Stroke</i> , 1996 , 27, 1163-6	6.7	49
93	A Two-Allele Polymorphism in Protein C Inhibitor with Varying Frequencies in Different Ethnic Populations. <i>Thrombosis and Haemostasis</i> , 1996 , 75, 062-069	7	5

92	Correlations among the DNA binding/cleaving specificities of small molecules revealed by double-strand affinity cleaving. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1995 , 5, 73-76	2.9	5
91	Comparative modeling of the three CP modules of the beta-chain of C4BP and evaluation of potential sites of interaction with protein S. <i>Protein Engineering, Design and Selection</i> , 1995 , 8, 1253-8	1.9	13
90	Two mutations in the promoter region of the human protein C gene both cause type I protein C deficiency by disruption of two HNF-3 binding sites. <i>Journal of Biological Chemistry</i> , 1995 , 270, 24216-21	5.4	34
89	General and Efficient Method for the Solution- and Solid-Phase Synthesis of Vancomycin Carboxamide Derivatives. <i>Journal of Organic Chemistry</i> , 1995 , 60, 1102-1103	4.2	42
88	Alternative PCR method for diagnosis of mutation causing activated protein C resistant Gln506-factor V. <i>Thrombosis Research</i> , 1995 , 80, 441-3	8.2	15
87	Anticoagulant response to activated protein C: method validation and assay comparison. <i>Journal of Clinical Laboratory Analysis</i> , 1995 , 9, 418-23	3	
86	Activated Protein C Resistance: Molecular Mechanisms. <i>Thrombosis and Haemostasis</i> , 1995 , 74, 444-448	7	56
85	Evolution of Sterol and Triterpene Cyclases. <i>ACS Symposium Series</i> , 1994 , 44-54	0.4	5
84	Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V. <i>New England Journal of Medicine</i> , 1994 , 331, 1559-62	59.2	116
83	Exonic polymorphisms in the protein C gene: interethnic comparison between Caucasians and Asians. <i>Human Genetics</i> , 1994 , 94, 177-8	6.3	3
82	Models of the serine protease domain of the human antithrombotic plasma factor activated protein C and its zymogen. <i>Protein Science</i> , 1994 , 3, 588-99	6.3	34
81	A structural model for the prostate disease marker, human prostate-specific antigen. <i>Protein Science</i> , 1994 , 3, 2033-44	6.3	65
80	Structural basis for type I and type II deficiencies of antithrombotic plasma protein C: patterns revealed by three-dimensional molecular modelling of mutations of the protease domain. <i>Proteins: Structure, Function and Bioinformatics</i> , 1994 , 18, 367-80	4.2	34
79	Analysis of protein S C4b-binding protein interactions by homology modeling and inhibitory antibodies. <i>Biochemistry</i> , 1994 , 33, 11073-8	3.2	19
78	Protein S binds to and inhibits factor Xa. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994 , 91, 2728-32	11.5	130
77	Protein C inhibitor is expressed in tubular cells of human kidney. <i>Journal of Clinical Investigation</i> , 1994 , 94, 2117-24	15.9	40
76	Possible Structural Implications of 20 Mutations in the Protein C Protease Domain. <i>Thrombosis and Haemostasis</i> , 1994 , 72, 869-873	7	5
75	Generation of activated protein C during thrombolysis. <i>Lancet, The</i> , 1993 , 342, 1275-6	40	21

74	Specific DNA cleavage mediated by manganese complex [SalenMn(III)] ⁺ . <i>Journal of Organic Chemistry</i> , 1993 , 58, 820-822	4.2	80
73	A novel exosite in the light chain of human activated protein C essential for interaction with blood coagulation factor Va. <i>Biochemistry</i> , 1993 , 32, 12656-63	3.2	31
72	Interactions and inhibition of blood coagulation factor Va involving residues 311-325 of activated protein C. <i>Protein Science</i> , 1993 , 2, 1482-9	6.3	25
71	Protein S, an antithrombotic factor, is synthesized and released by neural tumor cells. <i>Journal of Neurochemistry</i> , 1993 , 61, 344-7	6	23
70	Evidence for the Regulation of Urokinase and Tissue Type Plasminogen Activators by the Serpin, Protein C Inhibitor, in Semen and Blood Plasma. <i>Thrombosis and Haemostasis</i> , 1993 , 70, 0989-0994	7	40
69	High molecular weight kininogen receptor. <i>Methods in Enzymology</i> , 1992 , 215, 369-82	1.7	4
68	Nucleotide and deduced amino acid sequences of the oxidosqualene cyclase from <i>Candida albicans</i> . <i>Journal of the American Chemical Society</i> , 1992 , 114, 9711-9713	16.4	72
67	The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. <i>FEBS Journal</i> , 1992 , 208, 171-8		59
66	Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. <i>Circulation</i> , 1991 , 84, 2454-62	16.7	55
65	Complexes of activated protein C with alpha 1-antitrypsin in normal pregnancy and in severe preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 1991 , 164, 1310-6	6.4	24
64	Interaction of Plasma Kallikrein with Protein C Inhibitor in Purified Mixtures and in Plasma. <i>Thrombosis and Haemostasis</i> , 1991 , 65, 046-051	7	14
63	Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. <i>Circulation</i> , 1990 , 82, 578-85	16.7	120
62	Elucidating the structural chemistry of glycosaminoglycan recognition by protein C inhibitor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990 , 87, 8506-10	11.5	62
61	Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. <i>Thrombosis Research</i> , 1990 , 59, 593-608	8.2	71
60	Purification and characterization of plasma protein C inhibitor. <i>Thrombosis Research</i> , 1989 , 55, 369-84	8.2	86
59	Aprotinin (trasylol) is a competitive inhibitor of activated protein C. <i>Thrombosis Research</i> , 1989 , 56, 751-62		65
58	Determination of functional and antigenic protein C inhibitor and its complexes with activated protein C in plasma by ELISA. <i>Thrombosis Research</i> , 1989 , 55, 671-82	8.2	48
57	Functional Assays for Protein C Activity and Protein C Inhibitor Activity in Plasma. <i>Thrombosis and Haemostasis</i> , 1989 , 61, 086-092	7	8

56	Immunoblotting studies of the molecular forms of protein C in plasma. <i>Thrombosis Research</i> , 1988 , 52, 33-43	8.2	49
55	Competition of activated protein C and urokinase for a heparin-dependent inhibitor. <i>FASEB Journal</i> , 1988 , 2, 2263-7	0.9	12
54	Detection and Quantitation of Cleaved and Uncleaved High Molecular Weight Kininogen in Plasma by Ligand Blotting with Radiolabeled Plasma Prekallikrein or Factor XI. <i>Thrombosis and Haemostasis</i> , 1988 , 59, 151-161	7	26
53	Immunoblotting studies of coagulation factor XII, plasma prekallikrein, and high molecular weight kininogen. <i>Seminars in Thrombosis and Hemostasis</i> , 1987 , 13, 106-14	5.3	9
52	Sulfatide bilayers as a surface for contact activation in human plasma. <i>Biochemical and Biophysical Research Communications</i> , 1987 , 149, 1002-7	3.4	7
51	Studies on the effect of serine protease inhibitors on activated contact factors. Application in amidolytic assays for factor XIIa, plasma kallikrein and factor XIa. <i>FEBS Journal</i> , 1987 , 164, 637-42		37
50	Enhanced specificity of immunoblotting using radiolabeled antigen overlay: studies of blood coagulation factor XII and prekallikrein in plasma. <i>Analytical Biochemistry</i> , 1986 , 156, 118-25	3.1	20
49	Effects of subperineurial injections of very-long-chain and medium-chain fatty acids into rat sciatic nerve. <i>Neurochemical Pathology</i> , 1986 , 5, 71-83		3
48	Binding of coagulation factor XI to washed human platelets. <i>Biochemistry</i> , 1986 , 25, 3884-90	3.2	91
47	Effect of L-asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin K-dependent coagulation factors and inhibitors. <i>Journal of Pediatrics</i> , 1986 , 108, 698-701	3.6	39
46	Chapter 5A Initiation mechanisms: The contact activation system in plasma. <i>New Comprehensive Biochemistry</i> , 1986 , 103-128		4
45	Characterization of a variant prekallikrein, prekallikrein Long Beach, from a family with mixed cross-reacting material-positive and cross-reacting material-negative prekallikrein deficiency. <i>Journal of Clinical Investigation</i> , 1986 , 78, 170-6	15.9	14
44	Quantitative Immunoblotting of Plasma and Platelet Protein S. <i>Thrombosis and Haemostasis</i> , 1986 , 56, 382-386	7	9
43	The function of the heavy and light chain of human plasma kallikrein in the activation of factor XII. <i>Advances in Experimental Medicine and Biology</i> , 1986 , 198 Pt B, 27-34	3.6	0
42	Surface-dependent activation of human factor XII (Hageman factor) by kallikrein and its light chain. <i>FEBS Journal</i> , 1985 , 151, 531-8		26
41	The effect of tryptase from human mast cells on human prekallikrein. <i>Biochemical and Biophysical Research Communications</i> , 1985 , 129, 76-81	3.4	17
40	Formation of the Fibrin Clot: the Balance of Procoagulant and Inhibitory Factors. <i>Clinics in Haematology</i> , 1985 , 14, 281-342		38
39	A Protein S Deficient Family with Portal Vein Thrombosis. <i>Thrombosis and Haemostasis</i> , 1985 , 54, 724-724		25

38	Clinical studies of protein C. <i>Seminars in Thrombosis and Hemostasis</i> , 1984 , 10, 162-6	5.3	60
37	Receptors for high molecular weight kininogen on stimulated washed human platelets. <i>Biochemistry</i> , 1984 , 23, 6863-9	3.2	95
36	Studies on human protein C inhibitor in normal and Factor V/VIII deficient plasmas. <i>Thrombosis Research</i> , 1984 , 36, 197-203	8.2	20
35	Overview on Blood Coagulation Proteins 1984 , 39-55		
34	Interaction of human plasma kallikrein and its light chain with C1 inhibitor. <i>Biochemistry</i> , 1983 , 22, 4860-6	2.2	43
33	A comparison of the abilities of plasma kallikrein, beta-Factor XIIa, Factor XIa and urokinase to activate plasminogen. <i>Thrombosis Research</i> , 1983 , 29, 407-17	8.2	84
32	MECHANISMS FOR THE CONVERSION OF BLOOD COAGULATION PROENZYMES TO ENZYMES 1983 , 201-224		
31	The biochemistry and pathophysiology of the contact system of plasma. <i>Advances in Immunology</i> , 1982 , 33, 241-306	5.6	112
30	Platelet-coagulant protein interactions in contact activation. <i>Annals of the New York Academy of Sciences</i> , 1981 , 370, 241-52	6.5	10
29	Human protein C: inactivation of factors V and VIII in plasma by the activated molecule. <i>Annals of the New York Academy of Sciences</i> , 1981 , 370, 303-10	6.5	59
28	Alternative pathways of thromboplastin-dependent activation of human factor X in plasma. <i>Annals of the New York Academy of Sciences</i> , 1981 , 370, 325-35	6.5	11
27	Deficiency of protein C in congenital thrombotic disease. <i>Journal of Clinical Investigation</i> , 1981 , 68, 1370-3	3.9	835
26	Activation of rabbit Hageman factor by homogenates of cultured rabbit endothelial cells. <i>Journal of Clinical Investigation</i> , 1980 , 65, 197-206	15.9	56
25	Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. <i>Biochemistry</i> , 1980 , 19, 1151-60	3.2	94
24	Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease. <i>Journal of Clinical Investigation</i> , 1980 , 66, 1186-9	15.9	155
23	Molecular assembly in the contact phase of the Hageman factor system. <i>American Journal of Medicine</i> , 1979 , 67, 657-64	2.4	66
22	Rabbit blood coagulation factor XI. Purification and properties. <i>Thrombosis Research</i> , 1979 , 15, 475-86	8.2	20
21	Rabbit blood coagulation factor XI. Mechanism of activation of rabbit Hageman factor (factor XII). <i>Thrombosis Research</i> , 1979 , 15, 487-95	8.2	9

20	Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII. <i>Journal of Clinical Investigation</i> , 1979 , 64, 1056-65	15.9	115
19	Recent advances in the understanding of contact activation reactions. <i>Seminars in Thrombosis and Hemostasis</i> , 1979 , 5, 254-73	5.3	99
18	Circulating inhibitors of blood coagulation associated with procainamide-induced lupus erythematosus. <i>American Journal of Hematology</i> , 1978 , 4, 401-7	7.1	19
17	Evidence for the participation of both activated factor XII and activated factor IX in cold-promoted activation of factor VII. <i>Thrombosis Research</i> , 1978 , 13, 1049-56	8.2	34
16	Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. <i>Journal of Experimental Medicine</i> , 1978 , 147, 719-29	16.6	125
15	Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1978 , 75, 1998-2002	11.5	195
14	The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen. <i>Journal of Clinical Investigation</i> , 1977 , 59, 1167-75	15.9	123
13	Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1977 , 74, 4636-40	11.5	151
12	Carbon-13 nuclear magnetic resonance studies of the binding of selectively 13C-enriched oxytocins to the neurohypophyseal protein, bovine neurophysin II. <i>Biochemistry</i> , 1977 , 16, 4194-8	3.2	16
11	Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1976 , 73, 2554-8	11.5	220
10	Human factor XII (Hageman factor). <i>Methods in Enzymology</i> , 1976 , 45, 56-65	1.7	80
9	Studies of bovine neurophysin-neurohypophyseal hormone interactions. <i>Annals of the New York Academy of Sciences</i> , 1975 , 248, 463-79	6.5	13
8	Drug-biomolecule interactions: proton magnetic resonance studies of complex formation between bovine neurophysins and oxytocin at molecular level. <i>Journal of Pharmaceutical Sciences</i> , 1975 , 64, 507-11	3.9	4
7	Application of nuclear magnetic resonance spectroscopy to proteins. <i>Biochimie</i> , 1975 , 57, 453-60	4.6	2
6	Carbon-13 nuclear magnetic resonance studies on (85 per cent 13C-enriched Gly 9) oxytocin. <i>FEBS Letters</i> , 1975 , 50, 168-71	3.8	14
5	Interactions of Bovine Neurophysin II with Oxytocin and [8-Lysine] Vasopressin. <i>Journal of Biological Chemistry</i> , 1974 , 249, 6895-6900	5.4	15
4	Nuclear magnetic resonance studies of a ribonuclease-dinucleoside phosphonate complex and their implications for the mechanism of the enzyme. <i>Annals of the New York Academy of Sciences</i> , 1973 , 222, 693-708	6.5	34
3	The assignment of an exchangeable low-field NH proton resonance of ribonuclease A to the active-site histidine-119. <i>Biochemistry</i> , 1973 , 12, 2096-9	3.2	26

2	Complex Formation between Bovine Neurophysin-I and Oxytocin, Vasopressin, and Tripeptide Analogs of Their NH ₂ -terminal Region. <i>Journal of Biological Chemistry</i> , 1973 , 248, 7975-7978	5.4	26
1	Hormonal interactions at the molecular level: A high resolution proton magnetic resonance study of bovine neurophysins and their interactions with oxytocin. <i>FEBS Letters</i> , 1972 , 25, 282-286	3.8	20